---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055912"
form_type: "8-K"
ticker: "MASS"
cik: "0001555279"
company_name: "908 Devices Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:37:59.923884+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 908 Devices Q1 rev +14% to $13.4M, raises FY26 outlook; buys NIRLAB for $15M

## Summary
- Q1 revenue $13.4M (+14% YoY); recurring revenue $4.0M (30% of total); gross margin 51%, adj. 57%.
- Net loss from cont. ops $12.0M; adj. EBITDA loss $2.5M vs $4.6M loss a year ago; cash $111.7M, no debt.
- FY2026 revenue guidance raised to $67-70M (19-25% growth); installed base 3,903 devices (+23% YoY).
- Completed acquisition of NIRLAB AG for $15M ($13M cash + $2M stock) plus up to $8M earn-out in stock.
- NIRLAB adds NIR spectroscopy for narcotics; over 1M analyses; expands international and subscription revenue.

## SEC filing metadata
- accession: 0001104659-26-055912
- form_type: 8-K
- ticker: MASS
- cik: 0001555279
- company_name: 908 Devices Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/tm2613572d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055912
- JSON: https://secwatch.observer/filing/0001104659-26-055912.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055912.txt

## Key facts
- Earnings Releases
  908 Devices Inc. reported first quarter and three months ended March 31, 2026 results: revenue $13.4 million, net income Net loss attributable to common stockholders was $12.0 million. Guidance raised.
  - Period: first quarter and three months ended March 31, 2026
  - Revenue: $13.4 million
  - Net income: Net loss attributable to common stockholders was $12.0 million
  - Guidance: raised
  - Result: reported results
  source text: subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.” Recent Highlights · Revenue of $13.4 million for the first quarter of 2026, increasing 14% year over year · Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter · Gross margin was 51% and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm
- M&A Transactions
  908 Devices Inc. completed an acquisition involving Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod for headline price of $15,000,000 (closed 2026-05-04).
  - Action: acquisition
  - Counterparty: Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod
  - Consideration: headline price of $15,000,000
  - Closing: 2026-05-04
  source text: and outstanding NIRLAB Shares in exchange for a preliminary consideration (the “Preliminary Consideration”) payable by the Company on the Closing Date with a headline price of $15,000,000 (the “Transaction”), comprised of (x) $13,000,000 in cash (the “Cash Consideration”) and (y) 293,368 shares of common stock of the Company, par value $0.001 per share (each such
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm
- Material Agreements
  908 Devices Inc. entered into Share Purchase Agreement with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod valued at headline price of $15,000,000 (effective 2026-05-04).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod
  - Value: headline price of $15,000,000
  - Effective: 2026-05-04
  source text: On May 4, 2026 (the “Closing Date”), 908 Devices Inc. (the “Company”) completed its acquisition of NIRLAB SA, a corporation organized under the laws of Switzerland (“NIRLAB”), and its wholly owned subsidiary, NIRLAB Forensics Sàrl, a limited liability company organized under the laws of Switzerland (the “Subsidiary” and, together with NIRLAB, the “NIRLAB Group”), pursuant to a Share Purchase Agreement (the “Purchase Agreement”) with Florentin Coppey, Pierre Esseiva, Matteo Delbrück, Parkview Invest AG and Matthieu Girod (each a “Seller” and collectively, the “Sellers”) and NIRLAB.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555279/000110465926055912/0001104659-26-055912-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.